Nature Biotechnology:微软和剑桥科学家联手开发白血病发生电脑模型

2015-02-17 佚名 生物谷

一直以来,科学家们都希望从根源上认识白血病的致病机理。最近来自微软公司和剑桥大学的研究人员们构建了一个电脑模型用于模拟血细胞的整个发育过程。这也使模拟白血病相关基因在血细胞发育过程中是如何表达并最终导致白血病发生成为了可能。这一方法为今后的研究人员更好认识白血病以及其他血液疾病的致病机理提供了一个更便捷的工具。 在最近一期的Nature Biotechnology中,微软和剑桥大学的科学家介绍他

一直以来,科学家们都希望从根源上认识白血病的致病机理。最近来自微软公司和剑桥大学的研究人员们构建了一个电脑模型用于模拟血细胞的整个发育过程。这也使模拟白血病相关基因在血细胞发育过程中是如何表达并最终导致白血病发生成为了可能。这一方法为今后的研究人员更好认识白血病以及其他血液疾病的致病机理提供了一个更便捷的工具。

在最近一期的Nature Biotechnology中,微软和剑桥大学的科学家介绍他们首先测定了3900个造血干细胞的基因活性,并将获得的数据进行综合构建出了一个模型。科学家声称利用这个模型,研究人员能够进行一些简单、快速的模拟实验,而在实验室中这些实验一般耗时长达数周之久。例如在关于Hox和Sox两种基因在白血病发生中所扮演的角色上,这种新型的模型预测结果与实验结果就达到了良好的一致性。

研究人员希望今后这种模型能够用于更多疾病的研究上。

原始出处

Moignard V1, Woodhouse S1, Haghverdi L2, Lilly AJ3, Tanaka Y4, Wilkinson AC1, Buettner F5, Macaulay IC6, Jawaid W7, Diamanti E1, Nishikawa SI8, Piterman N9, Kouskoff V3, Theis FJ2, Fisher J10, Göttgens B1.Decoding the regulatory network of early blood development from single-cell gene expression measurements.Nat Biotechnol. 2015 Feb 9.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1927620, encodeId=029d192e6205e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jul 15 23:11:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717432, encodeId=037b1e174325f, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Mar 29 19:11:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652126, encodeId=a35d165212699, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 18 13:11:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795578, encodeId=c5e91e95578e9, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 30 22:11:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722267, encodeId=c4a91e22267bc, content=<a href='/topic/show?id=234b5081072' target=_blank style='color:#2F92EE;'>#微软#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50810, encryptionId=234b5081072, topicName=微软)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754533248452, createdName=huirong, createdTime=Tue May 26 00:11:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917131, encodeId=2321191e131c4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 21 03:11:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880513, encodeId=d12c188051365, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 28 17:11:00 CST 2015, time=2015-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16294, encodeId=0fab162943f, content=太过基础了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=49.4.167.**, createdTime=Tue Feb 17 13:04:00 CST 2015, time=2015-02-17, status=1, ipAttribution=)]
    2015-07-15 cathymary
  2. [GetPortalCommentsPageByObjectIdResponse(id=1927620, encodeId=029d192e6205e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jul 15 23:11:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717432, encodeId=037b1e174325f, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Mar 29 19:11:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652126, encodeId=a35d165212699, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 18 13:11:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795578, encodeId=c5e91e95578e9, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 30 22:11:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722267, encodeId=c4a91e22267bc, content=<a href='/topic/show?id=234b5081072' target=_blank style='color:#2F92EE;'>#微软#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50810, encryptionId=234b5081072, topicName=微软)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754533248452, createdName=huirong, createdTime=Tue May 26 00:11:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917131, encodeId=2321191e131c4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 21 03:11:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880513, encodeId=d12c188051365, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 28 17:11:00 CST 2015, time=2015-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16294, encodeId=0fab162943f, content=太过基础了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=49.4.167.**, createdTime=Tue Feb 17 13:04:00 CST 2015, time=2015-02-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1927620, encodeId=029d192e6205e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jul 15 23:11:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717432, encodeId=037b1e174325f, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Mar 29 19:11:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652126, encodeId=a35d165212699, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 18 13:11:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795578, encodeId=c5e91e95578e9, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 30 22:11:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722267, encodeId=c4a91e22267bc, content=<a href='/topic/show?id=234b5081072' target=_blank style='color:#2F92EE;'>#微软#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50810, encryptionId=234b5081072, topicName=微软)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754533248452, createdName=huirong, createdTime=Tue May 26 00:11:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917131, encodeId=2321191e131c4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 21 03:11:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880513, encodeId=d12c188051365, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 28 17:11:00 CST 2015, time=2015-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16294, encodeId=0fab162943f, content=太过基础了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=49.4.167.**, createdTime=Tue Feb 17 13:04:00 CST 2015, time=2015-02-17, status=1, ipAttribution=)]
    2015-12-18 shock_melon
  4. [GetPortalCommentsPageByObjectIdResponse(id=1927620, encodeId=029d192e6205e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jul 15 23:11:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717432, encodeId=037b1e174325f, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Mar 29 19:11:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652126, encodeId=a35d165212699, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 18 13:11:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795578, encodeId=c5e91e95578e9, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 30 22:11:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722267, encodeId=c4a91e22267bc, content=<a href='/topic/show?id=234b5081072' target=_blank style='color:#2F92EE;'>#微软#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50810, encryptionId=234b5081072, topicName=微软)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754533248452, createdName=huirong, createdTime=Tue May 26 00:11:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917131, encodeId=2321191e131c4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 21 03:11:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880513, encodeId=d12c188051365, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 28 17:11:00 CST 2015, time=2015-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16294, encodeId=0fab162943f, content=太过基础了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=49.4.167.**, createdTime=Tue Feb 17 13:04:00 CST 2015, time=2015-02-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1927620, encodeId=029d192e6205e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jul 15 23:11:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717432, encodeId=037b1e174325f, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Mar 29 19:11:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652126, encodeId=a35d165212699, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 18 13:11:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795578, encodeId=c5e91e95578e9, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 30 22:11:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722267, encodeId=c4a91e22267bc, content=<a href='/topic/show?id=234b5081072' target=_blank style='color:#2F92EE;'>#微软#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50810, encryptionId=234b5081072, topicName=微软)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754533248452, createdName=huirong, createdTime=Tue May 26 00:11:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917131, encodeId=2321191e131c4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 21 03:11:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880513, encodeId=d12c188051365, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 28 17:11:00 CST 2015, time=2015-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16294, encodeId=0fab162943f, content=太过基础了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=49.4.167.**, createdTime=Tue Feb 17 13:04:00 CST 2015, time=2015-02-17, status=1, ipAttribution=)]
    2015-05-26 huirong
  6. [GetPortalCommentsPageByObjectIdResponse(id=1927620, encodeId=029d192e6205e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jul 15 23:11:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717432, encodeId=037b1e174325f, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Mar 29 19:11:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652126, encodeId=a35d165212699, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 18 13:11:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795578, encodeId=c5e91e95578e9, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 30 22:11:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722267, encodeId=c4a91e22267bc, content=<a href='/topic/show?id=234b5081072' target=_blank style='color:#2F92EE;'>#微软#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50810, encryptionId=234b5081072, topicName=微软)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754533248452, createdName=huirong, createdTime=Tue May 26 00:11:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917131, encodeId=2321191e131c4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 21 03:11:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880513, encodeId=d12c188051365, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 28 17:11:00 CST 2015, time=2015-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16294, encodeId=0fab162943f, content=太过基础了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=49.4.167.**, createdTime=Tue Feb 17 13:04:00 CST 2015, time=2015-02-17, status=1, ipAttribution=)]
    2015-06-21 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=1927620, encodeId=029d192e6205e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jul 15 23:11:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717432, encodeId=037b1e174325f, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Mar 29 19:11:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652126, encodeId=a35d165212699, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 18 13:11:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795578, encodeId=c5e91e95578e9, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 30 22:11:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722267, encodeId=c4a91e22267bc, content=<a href='/topic/show?id=234b5081072' target=_blank style='color:#2F92EE;'>#微软#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50810, encryptionId=234b5081072, topicName=微软)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754533248452, createdName=huirong, createdTime=Tue May 26 00:11:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917131, encodeId=2321191e131c4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 21 03:11:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880513, encodeId=d12c188051365, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 28 17:11:00 CST 2015, time=2015-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16294, encodeId=0fab162943f, content=太过基础了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=49.4.167.**, createdTime=Tue Feb 17 13:04:00 CST 2015, time=2015-02-17, status=1, ipAttribution=)]
    2015-08-28 liye789132251
  8. [GetPortalCommentsPageByObjectIdResponse(id=1927620, encodeId=029d192e6205e, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Wed Jul 15 23:11:00 CST 2015, time=2015-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717432, encodeId=037b1e174325f, content=<a href='/topic/show?id=6089e177842' target=_blank style='color:#2F92EE;'>#白血病发生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71778, encryptionId=6089e177842, topicName=白血病发生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=961832410013, createdName=huperzia, createdTime=Sun Mar 29 19:11:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652126, encodeId=a35d165212699, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Fri Dec 18 13:11:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795578, encodeId=c5e91e95578e9, content=<a href='/topic/show?id=87881e249e8' target=_blank style='color:#2F92EE;'>#Technology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17249, encryptionId=87881e249e8, topicName=Technology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Jun 30 22:11:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722267, encodeId=c4a91e22267bc, content=<a href='/topic/show?id=234b5081072' target=_blank style='color:#2F92EE;'>#微软#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50810, encryptionId=234b5081072, topicName=微软)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=754533248452, createdName=huirong, createdTime=Tue May 26 00:11:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917131, encodeId=2321191e131c4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 21 03:11:00 CST 2015, time=2015-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880513, encodeId=d12c188051365, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Aug 28 17:11:00 CST 2015, time=2015-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16294, encodeId=0fab162943f, content=太过基础了, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=49.4.167.**, createdTime=Tue Feb 17 13:04:00 CST 2015, time=2015-02-17, status=1, ipAttribution=)]
    2015-02-17 49.4.167.**

    太过基础了

    0

相关资讯

Exp Hematol:研究发现白血病新的治疗靶点

新加坡癌症科学研究所和新加坡国立大学(NUS)科学家一项新研究发现参与急性髓系白血病(AML)的两个分子(STAT3和PRL-3)之间的新相互作用,提供了一个新的治疗靶点用于治疗此类癌症。 科学家们发现STAT3能潜在调节PRL-3的水平,后者是涉及多种类型癌症的基因。该研究发表在Experimental Hematology杂志上。 副教授Chng Wee Joo率领的研究小组第一次发现

国家自然科学基金重大项目“白血病状态下正常造血干/祖细胞的生物学行为及其调控机制”结题验收会议顺利召开

国家自然科学基金重大项目“白血病状态下正常造血干/祖细胞的生物学行为及其调控机制”验收会议于2015年2月2日在天津召开。国家自然科学基金委员会医学科学部孙瑞娟副主任到会并介绍了重大项目的定位、总体目标、实施管理要求、以及项目验收工作的重点。由9位来自全国不同单位的专家组成的验收组认真听取了项目负责人和课题负责人的汇报,讨论并形成了结题验收意见。 该重大项目的负责人由中国医学科学院血液病研究所程

Cell Metab:白血病、炎症治疗的新策略

根据华盛顿大学医学院一项新的研究证实:与糖尿病和肥胖相关的酶可能在关节炎和白血病中发挥关键作用,这就有可能开辟治疗这些疾病的新途径。 利用遗传工程小鼠开展的研究工作,研究人员发现参与将碳水化合物转化为脂肪的酶也影响特定白细胞即中性粒细胞的健康。嗜中性粒细胞是最丰富的类型的白血细胞,其是炎症的标志,而炎症是类风湿关节炎的一个关键组成部分。异常高水平的中性粒细胞在白血病患者也常见。 这项研究发表在

J Clin Invest:化疗耐受的急性淋巴细胞性白血病治疗新希望

急性淋巴细胞性白血病(ALL)是儿童白血病最常见的形式。治疗方案主要以化疗为主。可对化疗药物的耐受却是当今ALL治疗一直难以克服的一个障碍。美国洛杉矶儿童医院的科研究员最近设计并开发了一种以新型蛋白质为基础的治疗,被证实对耐药的白血病细胞非常有效。这篇研究近日在线发表在Journal of Clinical Investigation。 15岁以下儿童癌症患者有25%都是ALL患者。历史上A

Nature:阿西替尼或可用于治疗耐药性的白血病

近日,一篇发表于国际著名杂志Nature上的研究论文中,来自芬兰赫尔辛基大学等处的研究人员通过研究发现辉瑞公司生产的药物阿西替尼的潜在未知的功能,研究者表示该药物或许可以作为显性突变的一种潜在抑制剂,而显性突变往往会引发特定类型的白血病患者出现药物耐受性。 文章中,研究人员对来自慢性髓性白血病和急性淋巴细胞白血病患者机体的癌细胞进行分析研究,这些患者已经对当前的疗法产生了耐药性,而且这两类白

JCO:早期乳腺癌化疗或增加白血病患病风险

美国研究报道称,早期乳腺癌行预防性化疗或辅助化疗后,罹患白血病的风险将增加,这也意味着额外的治疗并不一定能带来额外的生存获益。他们发现行辅助化疗或预防性化疗的早期乳腺癌患者 10 年罹患白血病累积风险为 0.5%,大约为之前研究报告的 2 倍。该报告的研究者是来自约翰霍普金斯大学医学院肿瘤学的荣誉教授 Judith Karp 博士,他在一份通讯稿中说,骨髓肿瘤如白血病的发病率低,这是毫无疑问的